OCEANIC-STROKE
2026
Factor XIa Inhibition with Asundexian in Acute Non-Cardioembolic Stroke or High-Risk TIA
In 12,327 patients with non-cardioembolic stroke or high-risk TIA, asundexian reduced recurrent ischemic stroke compared with placebo.
Result
Efficacy: Primary efficacy: time to first ischemic stroke. Primary safety: ISTH major bleeding.cause-specific HR 0.74 (95% CI 0.65-0.84) · P < 0.001
Safety: ISTH major bleedingHR 1.10 (CI 0.85-1.44) · P = 0.46
Below 1 favours asundexian, above 1 favours placebo.
Event rates Asundexian 6.2% vs placebo 8.4% (primary efficacy: time to first ischemic stroke. Primary safety: ISTH major bleeding.)
Also reported: 26% RRR; ARR 2.2%, source-stated NNT 53 (ARR 1.9% at 1 year).
- Design
- Phase 3, randomized, double-blind, placebo-controlled, event-driven trial; asundexian 50 mg once daily vs placebo added to single or dual antiplatelet therapy, started within 72 h of index event; 702 sites in 37 countries.
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Sharma M, et al. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026;394:1467-1479.doi 10.1056/nejmoa2513880